Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ESRRB | O95718 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 4/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13715266 | 1.00 | FFAR1 (0.48) | FFAR1ESR1ESR2OPRM1MAPT | |
| SCHEMBL13715262 | 1.00 | FFAR1 (0.48) | FFAR1ESR1ESR2OPRM1MAPT | |
| SCHEMBL9540511 | 0.86 | SLC6A2 (0.49) | FFAR1MAPTRAB9A | |
| SCHEMBL7548232 | 0.86 | SLC6A2 (0.49) | FFAR1MAPTRAB9A | |
| SCHEMBL7549866 | 0.86 | SLC6A2 (0.49) | FFAR1MAPTRAB9A | |
| SCHEMBL21688300 | 0.86 | FFAR1 (0.56) | FFAR1RAB9AALDH1A1 | |
| SCHEMBL2501419 | 0.82 | OPRD1 (0.48) | FFAR1RAB9A | |
| SCHEMBL9540445 | 0.82 | FFAR1 (0.43) | FFAR1ALDH1A1 | |
| SCHEMBL2504416 | 0.82 | OPRD1 (0.48) | FFAR1RAB9A | |
| SCHEMBL29454615 | 0.82 | OPRD1 (0.48) | FFAR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025053379-A1 | NOVEL COMPOUND AND USE THEREOF FOR TREATING PSORIASIS | 광주과학기술원 | 2025-03-13 | — | — | WO | disclosed |
| EP-3177282-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3177282-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-108017603-B | Tricyclic compounds and uses thereof | 株式会社蒂奥姆生物 | 2021-07-23 | — | — | CN | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| US-10662171-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662171-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-2963027-B1 | TRICYCLIC COMPOUND AND USE THEREOF | TIUMBIO CO LTD (KR) | 2018-12-26 | — | — | EP | disclosed |
| US-20170217920-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-08-03 | — | — | US | disclosed |
| US-20170217920-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-08-03 | — | — | US | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
| EP-2139843-A1 | SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS | Amgen, Inc (US) | 2010-01-06 | — | — | EP | disclosed |
| US-7572934-B2 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572934-B2 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572934-B2 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2008130514-A1 | SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS | AMGEN INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130514-A1 | SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS | AMGEN INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662171-B2 | Antidiabetic bicyclic compounds | GPR119, GPR65, GLP1R | FFAR1 14/4885ESR1 1547/4885ESR2 312/4885 |
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | FFAR1 18/4885ESR1 173/4885ESR2 83/4885 |
| US-20170217920-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, GPR65, GLP1R | FFAR1 14/4885ESR1 1547/4885ESR2 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.